Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment

Article, Review English OPEN
Satoshi Tanida; Tsutomu Mizoshita; Keiji Ozeki; Hironobu Tsukamoto; Takeshi Kamiya; Hiromi Kataoka; Daitoku Sakamuro; Takashi Joh;

Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downs... View more
  • References (42)
    42 references, page 1 of 5

    Muñoz, N., Franceschi, S.. Epidemiology of gastric cancer and perspectives for prevention. Salud Publica de Mexico. 1997; 39 (4): 318-330

    Inoue, M., Tsugane, S.. Epidemiology of gastric cancer in Japan. Postgraduate Medical Journal. 2005; 81 (957): 419-424

    Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H., Takeuchi, M.. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet Oncology. 2008; 9 (3): 215-221

    Rino, Y., Yukawa, N., Murakami, H., Wada, N., Yamada, R., Hayashi, T., Sato, T., Ohshima, T., Masuda, M., Imada, T.. A phase II study of S-1 monotherapy as a first-line combination therapy of S-1 plus cisplatin as a second-line therapy, and weekly paclitaxel monotherapy as a third-line therapy in patients with advanced gastric carcinoma: a second report. Clinical Medicine Insights. 2010; 4: 1-10

    Pyndiah, S., Tanida, S., Ahmed, K. M., Cassimere, E. K., Choe, C., Sakamuro, D.. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Science Signaling. 2011; 4 (166, article ra19)

    Sedletska, Y., Giraud-Panis, M. J., Malinge, J. M.. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Current Medicinal Chemistry. 2005; 5 (3): 251-265

    De Laat, W. L., Jaspers, N. G. J., Hoeijmakers, J. H. J.. Molecular mechanism of nucleotide excision repair. Genes and Development. 1999; 13 (7): 768-785

    Rosenberg, B., Van Camp, L., Krigas, T.. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965; 205 (4972): 698-699

    Rosenberg, B., VanCamp, L.. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Research. 1970; 30 (6): 1799-1802

    Cvitkovic, E., Misset, J. L.. Chemotherapy for ovarian cancer. The New England Journal of Medicine. 1996; 334 (19): 1269-1270

  • Related Organizations (1)
  • Metrics
Share - Bookmark